Novo Nordisk Battles Pricing Storm on Two Fronts as Canadian Generics and US Policy Converge

US TrumpRx portal adds 600+ generic drugs, Canada approves first Ozempic generics, pressuring Novo Nordisk stock (down 15% YTD) despite buyback and Wegovy pill launch.

The Danish drugmaker is caught in a pincer movement. While the White House escalates its campaign to drive down prescription costs, a separate challenge is mounting in Canada where first-ever generics for Ozempic have won approval. The twin threats have left Novo Nordisk's stock nursing a 15 percent year-to-date loss, even after a 10 percent rebound over the past month that brought the shares to €37.96 on Monday.

Washington's latest move came on Monday with the addition of more than 600 generic drugs to the TrumpRx.gov portal, an initiative launched in early 2026 to align US drug prices more closely with those in other developed nations. The platform funnels patients toward manufacturer sites and partners such as Amazon Pharmacy and Mark Cuban’s Cost Plus Drug Co., and already included branded products including Ozempic and Wegovy. The administration claims the portal has generated savings exceeding $400 million and attracted roughly 10 million visits. Critics from the Democratic camp dismiss TrumpRx as a "referral channel for Big Pharma," but the market reads the expansion as a clear signal that pricing pressure is politically entrenched, especially with midterm elections approaching.

Across the northern border, the competitive landscape is shifting even more dramatically. Canadian health authorities have authorised the first copycat versions of Ozempic from Dr. Reddy’s Laboratories and Apotex. Should a third generic manufacturer enter the market, local rules trigger an automatic 65 percent discount on Novo Nordisk’s list price — a hammer blow that analysts at Citi are already weighing. They rate the stock "Neutral" with a price target of 290 Danish kroner, citing the looming price erosion and intensifying competition in the obesity space. Those risks, Citi argues, overshadow the stronger-than-expected launch of the Wegovy pill.

Novo Nordisk has responded with capital discipline. The current buyback programme, totalling up to 15 billion Danish kroner, saw the company repurchase more than 1.2 million B-shares at around 300 kroner in the latest reported week. Since February, it has bought back roughly 16 million shares, pushing its treasury stock to 0.7 percent. The buyback provides a floor, yet does little to address the structural headwinds compressing valuation. At a market capitalisation of $197.88 billion, the stock trades at a forward price-earnings multiple of 10.4 — a far cry from the premium enjoyed during its growth heyday.

Operationally, the business remains highly profitable. Adjusted operating profit reached 32.858 billion kroner in the first quarter, but management expects full-year revenue to fall 4 to 12 percent, citing stronger US pricing pressure and greater generic competition. The recent data on Wegovy prescriptions illustrate both the opportunity and the challenge. Citigroup data show roughly 137,000 US prescriptions for the oral tablet in the 18th calendar week, down 4 percent week-on-week. That volume is still about one-and-a-half times that of the nearest competitor, but Eli Lilly is closing the gap. The FDA cleared Lilly’s Foundayo on April 1, and in its fourth week on the market it had already reached 10,248 prescriptions. Foundayo boasts manufacturing advantages and fewer dietary restrictions, while Wegovy’s oral form must be taken on an empty stomach — a meaningful inconvenience.

Looking further ahead, Novo Nordisk is pushing the next generation of therapies. Clinical trials for the candidate Zenagamtide have commenced with two pivotal Phase 3 studies designed to demonstrate efficacy in obesity and type 2 diabetes over 84 weeks. Additional studies explore its potential in sleep apnoea and knee osteoarthritis. Yet those programmes remain years from the market.

The immediate proving ground arrives on August 5, when Novo Nordisk reports first-half results. Investors will scrutinise margin trends under the new competitive conditions and seek evidence that oral Wegovy sales can offset the price decay hitting older products. Until then, the stock remains hostage to two forces: the next round of White House price measures and weekly prescription data that will reveal whether the pill can sustain its early momentum. With Washington determined to keep drug costs in the spotlight and Canadian generics poised to rewrite the pricing rulebook, Novo Nordisk’s rich patent estate offers less shelter than it once did.